AstraZeneca Mergers and Acquisitions Summary

Life Science Company

AstraZeneca has acquired 13 companies, including 3 in the last 5 years. A total of 4 acquisitions came from private equity firms. It has also divested 11 assets.

AstraZeneca’s largest acquisition to date was in 2007, when it acquired MedImmune for $15.6B. It’s largest disclosed sale occurred in 2016, when it sold AstraZeneca - Small Molecule Anti-Infective Business to Pfizer for $550M. AstraZeneca has acquired in 5 different US states, and 6 countries. The Company’s most targeted sectors include life science (84%) and information technology (9%).

Join Mergr and gain access to AstraZeneca’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

M&A Summary

  • M&A Total Activity23
    • M&A Buy Activity12
    • M&A Sell Activity11
  • Total Sectors Invested 3
  • Total Countries Invested 6
  • M&A Buy/Sell Connections 17
  • M&A Advisors 1

AstraZeneca Plc

1 Francis Crick Avenue Cambridge Biomedical Campus,
London, CB2 0AA
United Kingdom,
+44 20 3749 5000
www.astrazeneca.com

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biologics company .AstraZeneca is an innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca was founded in 1992 and is based in Cambridge, the United Kingdom.


M&A Summary

Buy vs Sell

Year ≤ '15 '16 '17 '18 '19 '20 T
Buy (0.0/yr) # 12 - - - - - 12
vol $28.8B $28.8B
Sell (1.0/yr) # 6 2 - 2 1 - 11
vol $325M $725M $350M $1.4B
  23

Most Recent M&A

Company Date Value Type
Juvisé Pharmaceuticals - Arimidex & Casodex 2019-12-20 - Divestiture
Villeurbanne, France
AstraZeneca Plc - Alvesco, Omnaris and Zetonna Business 2018-11-06 350M USD Divestiture
London, United Kingdom
AstraZeneca Plc - Seroquel and Seroquel XR 2018-05-27 - Divestiture
London, United Kingdom
AstraZeneca Plc - Toprol-XL 2016-10-04 175M USD Divestiture
London, United Kingdom
AstraZeneca - Small Molecule Anti-Infective Business 2016-08-24 550M USD Divestiture
London, United Kingdom
Acerta Pharma BV 2015-12-17 4.0B USD Add-on Acquisition
Oss, Netherlands · www.acerta-pharma.com
Takeda Pharmaceutical Company - Core Respiratory Business 2015-12-16 575M USD Divestiture
, Japan
ZS Pharma, Inc. 2015-11-05 2.7B USD Add-on Acquisition
Coppell, Texas · www.zspharma.com
Caprelsa 2015-07-27 - Divestiture
, United Kingdom · www.caprelsarems.com
Myalept 2014-11-06 325M USD Divestiture
, United States · www.myaleptrems.com
View All >>

Business Unit M&A

Company Acquired Add-On/Sale Date #
MedImmune LLC 2007-06-01 Spirogen Ltd. 2013-10-15 3
Gaithersburg, Maryland · www.medimmune.com London, United Kingdom · www.spirogen.com
MedImmune LLC 2007-06-01 Amplimmune, Inc. 2013-08-26 2
Gaithersburg, Maryland · www.medimmune.com Gaithersburg, Maryland · www.amplimmune.com
MedImmune LLC 2007-06-01 AlphaCore Pharma LLC 2013-04-03 1
Gaithersburg, Maryland · www.medimmune.com Ann Arbor, Michigan · www.alphacorepharma.com

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 10 (83%) 13.1B (45%) 7 (64%) 900M (64%)
Medical Products 1 (8%) 15.6B (54%) 3 (27%) 325M (23%)
Information Technology 1 (8%) 150M (1%) - -
Healthcare Services - - 1 (9%) 175M (13%)
Total 12 $28.8B 11 $1.4B

By Geo

State/Country Buy Value Sell Value
United States 6 23.7B 3 325M
  California 2 2.4B - -
  Texas 1 2.7B - -
  New Jersey 1 323M - -
  Maryland 1 15.6B - -
United Kingdom 2 360M 5 1.1B
Sweden - - 2 -
Canada 1 - - -
France - - 1 -
Germany 1 150M - -
Japan 1 575M - -
Netherlands 1 4.0B - -
Domestic 2 (17%) 360M (1%) 5 (45%) 1.1B (77%)
Cross-border 10 (83%) 28.5B (99%) 6 (55%) 325M (23%)
Total 12 $28.8B 11 $1.4B

Top M&A Advisors

Financial Deals
Evercore Group LLC
1

Deal Values

buy # Total
> $1B 6 $27.4B
$100M to $1B 5 $1.4B
TOTAL $28.8B
Largest MedImmune LLC
$15.6B (2007-06-01)
sell # Total
$100M to $1B 4 $1.4B
TOTAL $1.4B
Largest AstraZeneca - Small Molecule Anti-Infective Business
$550M (2016-08-24)

M&A Connections

Deals %
Acquired from
PE Firm(s)
57%
4 57%
Strategic(s)
43%
3 43%
Divested to
Strategic(s)
100%
11 100%

 Subscribe to unlock this and 151,932
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.9K Private Equity Firms
  • 139K M&A Transactions
  • 148K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.1K M&A Advisors
    (Investment Banks and Law Firms)
  • 41K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.